Core Insights - MBX Biosciences has successfully completed an End-of-Phase 2 meeting with the FDA, confirming the design for a Phase 3 trial of canvuparatide for chronic hypoparathyroidism, set to begin in Q3 2026 [2][3] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders [2][8] - The company utilizes its proprietary Precision Endocrine Peptide™ (PEP™) platform technology to create novel therapies [6][8] Product Development - Canvuparatide is a parathyroid hormone peptide prodrug designed for once-weekly administration, aiming to restore physiologic PTH activity and maintain normocalcemia [6][7] - The Phase 3 trial will enroll approximately 160 patients, with a 3:1 randomization to receive canvuparatide or placebo, including a fixed dose period, dose-titration, and maintenance period [4][3] Market Potential - Chronic hypoparathyroidism affects over 250,000 individuals in the U.S. and Europe, with current treatments not addressing the underlying PTH deficiency [7] - Canvuparatide has received orphan drug designation from both the FDA and the European Medicines Agency, supporting its clinical development [5][6]
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism